Molecular formula: C225H348N48O68

Molar Mass: 4813.45 g/mol

Specification: 15 mg/vial

Purity (HPLC): 99.1%

Tirzepatide is a synthetic peptide and a dual receptor agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual action results in powerful synergistic effects on glucose metabolism, insulin sensitivity, and body weight regulation.

It acts by stimulating glucose-dependent insulin secretion, suppressing glucagon production, slowing gastric emptying, and significantly reducing appetite and food intake. Tirzepatide has been shown to be more effective than single-pathway peptides for fat loss and glycemic control, making it one of the most advanced investigational compounds in the metabolic category.

Key Properties of Tirzepatide:

• Dual GIP and GLP-1 receptor activation for superior metabolic regulation

• Powerful appetite suppression and extended satiety

• Significant reduction in body weight and visceral fat

• Enhanced insulin sensitivity and glycemic control

• Positive effect on lipid profiles and cardiometabolic markers

• Long-acting action, suitable for once-weekly subcutaneous injections

Suggested Use:

• Start dose: 2.5 mg once per week

• Gradual increase: Step up to 5 mg → 10 mg → 15 mg per week as tolerated

• Administered in the abdomen, thigh, or upper arm

• For research use only; dosage and titration depend on study protocol and individual tolerance

Important Notes:

• Common initial effects may include nausea, appetite suppression, or bloating — usually transient.

• Hydration and nutrient monitoring recommended during use.

• Not for use during pregnancy, lactation, or in individuals with a history of pancreatitis.

• Designed for research purposes only, not approved for medical use.